Vasu M Tumati

CURRENT Associate Physician **POSITION** Cancer Care Group

POST GRADUATE Radiation

TRAINING

Radiation Oncology

University of Texas Southwestern Medical Center

Dallas, TX 2014-2018

Internal Medicine - Preliminary

Norwalk Hospital Norwalk, CT 2013-2014

EDUCATION Doctor of Medicine

New York Medical College Valhalla, NY 2008-2013

Graduate Certificate in Clinical Sciences

University of Texas Southwestern Medical Center

Dallas, TX 2011-2012

Bachelor of Science in Biochemistry

Indiana University

Bloomington, Indiana, 2004-2007

RESEARCH Howard Hughes Medical Institute-IFLE

FELLOWSHIPS Doris Duke Clinical Research Fellow – UT-Southwestern

AWARDS & HONORS

Indiana University Hutton Honors College Indiana University Chemistry Honor Roll

UT Southwestern Clinical and Translational Science Award (TL1) Chief Resident – UTSW Department of Radiation Oncology

David A. Pistenmaa Award Winner Roentgen Resident Research Award

PROFESSIONAL SOCIETIES

American Society for Radiation Oncology American Society for Clinical Oncology

American Brachytherapy Society

FUNDING UTSW Cancer Center Developmental Grant

\$80,000 - 9/1/2016-8/31/2018

A Randomized Phase I/II Trial of SBRT with or without GC4419 for Centrally Located

or High Risk Early Stage NSCLC

NIH TL1- Grant #5TL1RR024984-05

21,400 - 7/7/2011-7/6/2012

Training Grant

PROTOCOLS A Randomized Phase I/II Trial of SBRT with or without GC4419 for Centrally Located

or High Risk Early Stage NSCLC

A Phase II Trial of Stereotactic Body Radiation Therapy for Locally Advanced Cervix

Cancer

Phase II Study of Enzalutamide and Gonadotropin-Releasing Hormone Agonist Before, During, and After Radiation Therapy in Treatment of Patients with High-Risk Localized

Prostate Cancer

PUBLICATIONS

<u>Vasu Tumati</u> and Puneeth Iyengar. *The Current State of Oligometastatic and Oligoprogressive Non-small Cell Lung Cancer*. (Accepted Journal of Thoracic Disease)

<u>Vasu Tumati</u>, Lakshya Trivedi, Hsiao-Ching Li, Prapti Patel, Pier Scaglioni, Madhuri Vusirikala, Navid Sadeghi, Syed Rizvi, Weina Chen, Jason Wachsmann, Robert Collins, Neil Desai. *Patterns of Failure in Patients with Double Hit or Double Expressor Lymphomas: Implications for Radiation Therapy*. Int J Radiat Oncol Biol Phys. 2018 Apr 1;100(5):1126-1132.

William C. Jackson, Krithika Suresh, <u>Vasu Tumati</u>, Robert T. Dess, Payal D. Soni, Shuang G. Zhao, Zachary S. Zumsteg, Raquibul Hannan, Brent K. Hollenbeck, Arvin George, Samuel D. Kaffenberger, Simpa S. Salami, Jason W.D. Hearn, Todd M. Morgan, Rohit Mehra, Matthew Schipper, Felix Y. Feng, Neil B. Desai, Daniel E. Spratt. *Impact of Biochemical Failure After Salvage Radiation Therapy on Prostate Cancer—specific Mortality: Competition Between Age and Time to Biochemical Failure*. European Urology Oncology, Volume 0, Issue 0

Musaddiq J Awan, Lucien Nedzi, Dian Wang, <u>Vasu Tumati</u>, Baran Sumer, Xian-Jin Xie, Irma Smith, John Truelson, Randall Hughes, Larry Myers, Pierre Lavertu, Stuart Wong, Min Yao. *Final Results of a Multi-institutional Phase II Trial of Re-Irradiation with Concurrent Weekly Cisplatin and Cetuximab for Recurrent or Second Primary Squamous Cell Carcinoma of the Head and Neck*. Ann Oncol. 2018 Apr 1;29(4):998-1003

Puneeth Iyengar, Zabi Wardak, David Gerber, <u>Vasu Tumati</u>, Chul Ahn, Randall Hughes, Jonathan Dowell, Naga Cheedella, Lucien Nedzi, Kenneth Westover, Suprabha Pulipparacharuvil, Hak Choy, and Robert Timmerman. *Consolidative Stereotactic Ablative Radiotherapy for Limited Metastatic Non-Small Cell Lung Cancer: A Randomized Phase II Trial.* JAMA Oncol. 2018 Jan 11;4(1):e173501

William C. Jackson, Krithika Suresh, <u>Vasu Tumati</u>, Steven G. Allen, Robert T. Dess, Simpa S. Salami, Arvin George, Samuel D. Kaffenberger, David C. Miller, Jason W.D. Hearn, Shruti Jolly, Rohit Mehra, Brent K. Hollenbeck, Ganesh S. Palapattu, Matthew Schipper, Felix Y. Feng, Todd M. Morgan, Neil B. Desai, Daniel E. Spratt. *Intermediate Endpoints After Post-Prostatectomy Radiotherapy: 5-year Distant Metastasis to Predict Overall Survival*. Eur Urol. 2018 Jan 3. pii: S0302-2838(17)31070-9.

<u>Vasu Tumati</u>, William C. Jackson, Ahmed Abugarib, Claus Roehrborn, Yair Lotan, Ganesh Raj, Aditya Bagrodia, Jeffrey Gahan, Kevin Courtney, Aaron Laine, Raquibul Hannan, Michael Folkert, Dan E. Spratt, Neil B. Desai. *Natural History of Men Who Failed Post Operative Radiation Therapy for Prostate Cancer.* BJU Int. *2017 Jun 5*

<u>Vasu Tumati</u> and Puneeth Iyengar. *SABR Rattling with Radiation and Surgery: Paving a Path Towards Refined Treatment of Early Stage NSCLC.* Journal of Oncology Practice 13, no. 2 (February 2017) 77-78.

Sunjana Gottumukala, <u>Vasu Tumati</u>, Brian Hrycushko. Michael R. Folkert. *Interstitial and Endoluminal Brachytherapy for GI Malignancies: A Systematic Review*. Curr Oncol Rep. 2017 Jan;19(1):2

William Jackson, Neil Desai, Ahmed Abugharib, <u>Vasu Tumati</u>, Robert T. Dess, Jae Y. Lee, Shuang G Zhao, Moaaz Soliman, Zachary Zumsteg, Howard Sandler, Jeffrey Montgomery, David Miller, Mike Kozminski, Brent Hollenbeck, Jason Hearn, Ganesh Palapattu, Scott Tomlins, Rohit Mehra, Todd Morgan, Felix Feng, Dan E. Spratt. *Anatomic Patterns of Recurrence Following Biochemical Relapse after Post-*

Prostatectomy Radiation Therapy: A Multi-Institutional Study. BJU Int. 2017 Jan 31

Ahmed Abugharib*, William C. Jackson*, <u>Vasu Tumati</u>, Robert T. Dess, Jae Y. Lee, Shuang G. Zhao, Payal D. Soni, Zachary S. Zumsteg, Howard Sandler, Dan Hamstra, Jason W. Hearn, Ganesh Palapattu, Scott A. Tomlins, Rohit Mehra, Felix Y. Feng, Todd M. Morgan, Neil Desai, Daniel E. Spratt. *Defining Early Salvage Radiotherapy: Long-term Follow-up From a Multi-center Study*. <u>J Urol.</u> 2016 Sep 7. pii: S0022-5347(16)31206-X

*Co-first authors

Raquibul Hannan, <u>Vasu Tumati</u>, Xian-Jie Xie, L. Chinsoo Cho, Brian D. Kavanagh, Jeffrey Brindle, David Raben, Akash Nanda, Susan Cooley, D.W. Nathan Kim, David Pistenmaa, Yair Lotan, Robert Timmerman. *Stereotactic Body Radiation Therapy for Low and Intermediate Risk Prostate Cancer – 5 Year Outcomes*. Eur J Cancer. 2016 Mar 29;59:142-151.

<u>Vasu Tumati</u>, Michael R. Folkert, Sandra Lawson, Elsa Wise, Sheila Wolcott, Debra Richardson, Matthew Carlson, Siobhan Kehoe, Jayanthi Lea, Ramzi Abdulrahman, Kevin Albuquerque. *Remote Location Interstitial Brachytherapy with Patient Stabilization and Subsequent Transport to an Outpatient Center is Safe and Effective for the Treatment of Gynecologic Malignancies*. Brachytherapy. 2016 Mar 19 (in press)

Corbin Jacobs, <u>Vasu Tumati</u>, Payal Kapur, Jingsheng Yan, Xian-Jin Xie, Raquibul Hannan, JT Hsieh, DW Nathan Kim, Debabrata Saha. *Pretreatment Biopsy Analysis of DAB2IP Identifies Subpopulation of High-Risk Prostate Cancer Patiens with Worse Survival Following Radiation Therapy*. Cancer Med. 2015 Dec;4(12):1844-52

Lan Yu, Zeng-Fu Shang, Feng-Min Hsu, Zhang Zhang, <u>Vasu Tumati</u>, Yu-Fen Lin, Benjamin Chen, Debabrata Saha. *NSCLC cells demonstrate differential mode of cell death in response to the combined treatment of radiation and a DNA-PKcs inhibitor*. Oncotarget. 2015 Feb 28;6(6):3848-60.

Jyothi Menon, <u>Vasu Tumati</u>, J.T. Hsieh, Kytai Nguyen, Debabrata Saha. *Polymeric Nanoparticles for Targeted Radiosensitization of Prostate Cancer Cells*. J Biomed Mater Res A. 2014 Aug 2.

Corbin Jacobs, <u>Vasu Tumati</u>, Payal Kapur, Jingsheng Yan, David Hong, Manzerul Bhuiyan, Xian-Jin Xie, David Pistenmaa, Lan Yu, J.T. Hsieh, Debabrata Saha, and D. Nathan Kim. <u>DOC-2/DAB2 Interacting Protein Status in High-Risk Prostate Cancer Correlates With Outcome for Patients Treated With Radiation Therapy. Int J Radiat Oncol Biol Phys. 2014 Jul 15;89(4):729-35</u>

<u>Vasu Tumati</u>, Subashri Kumar, Lan Yu, Benjamin Chen, Hak Choy, Debabrata Saha. *Crizotinib does not Enhance the Efficacy of Radiation Therapy in Non-Small Cell Lung Carcinoma Cells*. Oncology Reports. 2013 Mar;29(3):1094-100

<u>Vasu Tumati</u>, Sanjeev Mathur, JT Hsieh, Kwang Song, Dawen Zhao, Tim Solberg and Debabrata Saha. *Development of a Locally Advanced Orthotopic Prostate Tumor Model in Rats for Combined Modality Therapy*. International journal of oncology. 2013;42:1613-9

Lan Yu, <u>Vasu Tumati</u>, Feng-Ming Hsu, DW Kim, David Hong, Jer-Tsong Hsieh, Benjamin Chen, Debabrata Saha. *DAB2IP Regulates Prostate Cancer Cell Death Pathways in Response to Radiation in the Context of DNA-PKcs Inhibition*. Neoplasia. 2012 Dec;14(12):1203-12

<u>Vasu Tumati*</u>, Pavithra Raghavan*, Lan Yu, Norman Chan, Nozomi Tomimatsu, Sandeep Burma, Robert G. Bristow and Debabrata Saha. *AZD5438 an inhibitor of CDK 1, 2 and 9 enhances the radiosensitivity of non small cell lung carcinoma cells*. Int J Radiat Oncol Biol Phys. 2012 Nov 15;84(4):e507-14

*Co-first authors

ORAL PRESENTATIONS/ INVITED TALKS

Puneeth Iyengar, <u>Vasu Tumati</u>, Zabi Wardak, David Gerber, Chul Ahn, Randall Hughes, Jonathan Dowell, Naga Cheedella, Lucien Nedzi, Kenneth Westover, Suprabha Pulipparacharuvil, Hak Choy, and Robert Timmerman. *Consolidative Stereotactic Ablative Radiotherapy for Limited Metastatic Non-Small Cell Lung Cancer: A Randomized Phase II Trial.* American Society for Radiation Oncology Annual Meeting 2017 (Plenary)

V. Tumati, P. Raghavan, L. Yu, N. Chan, N. Tomimatsu, S. Burma, R.G. Bristow and D Saha. *AZD5438, an Inhibitor of CDK 1, 2, and 9, Enhances the Radiosensitivity of Non-Small Cell Lung Carcinoma Cells.* American Society for Radiation Oncology Annual Meeting 2012

<u>Vasu Tumati</u>, Lan Yu, and Debabrata Saha. *Mechanisms of Radiation Resistance and Radiation Sensitizing Strategies*. Doris Duke Charitable Foundation Annual Conference 2012

Kaleb Naegeli, <u>Vasu Tumati</u>, Michael Mand, Ching-Shih Chen, Samuel Kulp, Meiyun Fan, Kenneth Nephew, and Curtis Balch. *Novel mechanisms of ovarian cancer growth inhibition, via microRNA downregulation and oxidative damage, by a rationally designed histone deacetylase inhibitor*. American Association for Cancer Research Annual Meeting 2007

POSTER PRESENTATIONS

Lakshya Trivedi, <u>Vasu Tumati</u>, Hsiao-Ching Li, Prapti Patel, Pier Scaglioni, Madhuri Vusirikala, Navid Sadeghi, Syed Rizvi, Weina Chen, Jason Wachsmann, Robert Collins, Neil Desai. *Patterns of Failure in Patients with Double Hit or Double Expressor Lymphomas: Implications for Radiation Therapy.* American Society of Radiation Oncology Annual Meeting 2017

<u>Vasu Tumati</u>, Daniel Spratt, William Jackson, Felix Feng, Claus Roehrborn, Yair Lotan, David Pistenmaa, Aaron Laine, Michael Folkert, Raquibul Hannan, Neil Desai. *Natural History of Progression after Biochemical Failure Following Post-Operative Radiation Therapy in Prostate Cancer*. American Society of Radiation Oncology Annual Meeting 2016.

William C. Jackson, Neil Desai, <u>Vasu Tumati</u>, Dan Hamstra, Jae Y. Lee, Robert T. Dess, Howard Sandler, Ganesh Palapattu, Scott A. Tomlins, Rohit Mehra, Zachary S. Zumsteg, Todd M. Morgan, Felix Y. Feng, Daniel E. Spratt. *Anatomic Patterns of Recurrence Following Biochemical Relapse After Post-Prostatectomy Radiation Therapy: A Multi-Institutional Study*. American Society of Radiation Oncology Annual Meeting 2016.

William C. Jackson, Neil Desai, <u>Vasu Tumati</u>, Daniel A. Hamstra, Jae Y. Lee, Robert T. Dess, Payal D. Soni, Ahmed E. Abugharib, Jason W. Hearn, Howard Sandler, Zachary S. Zumsteg, Ganesh Palapattu, Scott A. Tomlins, Rohit Mehra, Todd M. Morgan, Felix Y. Feng, Daniel E. Spratt. *Predictors of Rapid Treatment Failure after Post-Operative Radiotherapy: A Multicenter Study*. American Society of Radiation Oncology Annual Meeting 2016.

Corbin Jacobs, <u>Vasu Tumati</u>, Payal Kapur, Raquibul Hannan, Jer-Tsong Hsieh, Dong Kim, Debabrata Saha. *Association of decreased tumor DAB2IP and High-Risk Prostate*

Cancer-Specific Survival. American Society of Clinical Oncology Annual Meeting 2016

<u>Vasu Tumati</u>, Corbin Jacobs, James Ying, Claus Roehrborn, Yair Lotan, Vitaly Margulis, David Pistenmaa, DW Nathan Kim, Raquibul Hannan. *Outcomes in High-Risk Prostate Cancer Patients Treated with Adjuvant versus Definitive Radiation Therapy*. American Society for Clinical Oncology Genitourinary Cancers Symposium 2016.

James Ying, <u>Vasu Tumati</u>, Jingsheng Yan, Xian-Jin Xie, Claus Roehrborn, Vitaly Margulis, David Pistenmaa, Raquibul Hannan, Kevin Choe, D.W. Nathan Kim. *High Presalvage Radiation Therapy PSA Strongly Correlates With Very Early Failure and Worse Outcomes*. American Society of Radiation Oncology Annual Meeting 2015.

Jyothi Menon, <u>Vasu Tumati</u>, Jer-Tsong Hsieh, Kytai Ngyuyen, Debabrata Saha. *Efficacy of NU7441-encapsulated PLGA Nanoparticles in Radiation Sensitization of Prostate Cancer Cells*. American Association of Cancer Research Annual Meeting 2014.

Yu Lan, Zengfu Shang, Feng-Ming Hsu, <u>Vasu Tumati</u>, Benjamin Chen, Debabrata Saha. *NSCLC Cells Demonstrate Differential Mode of Cell Death in Response to the Combined Treatment of Radiation and a DNA-PKcs Inhibitor*. American Association of Cancer Research Annual Meeting 2014.

Jacobs C, Kapur P, Yan J, <u>Tumati V</u>, Xie X, Pistenmaa D, Bhuiyan M, Hsieh JT, Saha D, Kim DN. *Tumor Status of DAB2IP but Not EZH2 Correlates With Biochemical Failure, Castrate Resistance, and Distant Metastases in High-risk Prostate Cancer Patients Treated With Radiation Therapy.* American Society for Radiation Oncology Annual Meeting 2013

V. Tumati, J. Dubas, A. Pompos, R. Abdulrahman, R. Timmerman, K. Albuquerque. Stereotactic Body Radiotherapy (SBRT) can be Dosimetrically Equivalent to High dose Brachytherapy as a Boost for Locally Advanced Cervical Cancer- A New Clinical Trial Concept. American Society for Radiation Oncology Annual Meeting 2012

D. Kim, <u>V. Tumati</u>, D. Pistenmaa, P. Kapur, X. Xie, R. Hannan, C. Jacobs, C. Straka, J. Hsieh, D. Saha. *Loss of Tumor Suppressor DAB2IP Correlates With Decreased Biochemical Recurrence Free Survival in High Risk Prostate Cancer Patients Treated With Radiation Therapy*.

American Society for Radiation Oncology Annual Meeting 2012

B. Mueller, C. Obcemea, <u>V.Tumati</u>, Y. Song, F. Devita. *Pilot Project For Comprehensive Chart Rounds Using A Telemedicine Platform*. American Society for Radiation Oncology Annual Meeting 2011

Mand, Michael, Edwards, Ceazon, <u>Tumati, Vasu</u>, Kulp, Samuel K., Chen, Ching-Shih, Nephew, Kenneth P., Balch, Curtis *A novel histone deacetylase inhibitor with potent antiproliferative activity in ovarian cancer cells*. American Association for Cancer Research Annual Meeting 2006